FDA says Essential Elements’ CholestAid supplement is an unapproved new drug and misbranded because website claims say it treats cholesterol and heart issues.
What happened
In August 2022, FDA reviewed Essential Elements’ website and Amazon storefront and found order pages for CholestAid. FDA cited claims that CholestAid reduces LDL cholesterol, manages cholesterol, lowers blood pressure, and affects cardiovascular issues. FDA said these claims show the supplement is intended as a drug for disease treatment or prevention.
What FDA found
Website claims that CholestAid lowers LDL cholesterol, manages cholesterol, and lowers blood pressure show it is intended to treat or prevent disease, which makes it a drug.
section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)]CholestAid is not generally recognized as safe and effective for these uses, so it is a new drug that needs FDA approval before sale.
sections 201(p), 301(d), and 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]CholestAid lacks adequate directions for use because its intended diseases are not suitable for self-diagnosis or treatment without a licensed practitioner, so it is misbranded.
section 502(f)(1) [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Introducing or delivering the misbranded drug into interstate commerce violates the Act.
section 301(a) [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to address the violations, including how it will prevent recurrence and related documentation. If corrective action cannot be completed in that time, the company must state why and give a completion date; if it believes there is no violation, it must explain and provide support.
Who should pay attention
- dietary supplement brands making disease claims
- Amazon sellers of supplements
- marketing and compliance teams reviewing website claims
This is a summary. Read the original letter on fda.gov.